课题基金 / 基金详情

Control of Tumor Growth by the MMP/Angiostatin Pathway

Control of Tumor Growth by the MMP/Angiostatin Pathway
MMP/血管抑制素途径控制肿瘤生长
批准号:
7339223
负责人:
AMBRA POZZI
金额:
$4.34万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-01-10 至 2007-12-31

项目摘要

项目成果

AMBRA POZZI的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Angiogenesis is essential for tumor growth and blocking this process is viewed as a valid tool for the control of cancer growth. We showed that in integrin _l-null mice tumor angiogenesis is reduced compared to that of wild type mice. This reduction is due to overexpression of matrix metaUoproteinases (MMPs) in the al-null and consequent generation of angiostatin (an inhibitor of endothelial cell growth) from plasminogen. Our findings, in contrast to the accepted role of MMPs being pro-tumorigenic, suggest that excess synthesis of MMPs may play opposite effects on tumor growth. On one hand, increased MMPs may promote cell migration and metastasis by inducing extracellular matrix degradation. On the other hand, increased MMPs may prevent tumor growth via angiostatin generation. We showed that inhibition of MMP expression in vivo leads to decreased synthesis of angiostatin and consequent increased tumor growth and vascularization. This observation, together with the disappointing results achieved by MMP inhibitors in the treatment of human cancers, suggests that MMP inhibitors used as anti-tumor drugs might in fact cause a paradoxical increase in tumor growth and angiogenesis by preventing the generation of inhibitors of endothelial cell growth. In addition, we also showed that integrin otl is directly involved in the control of cell proliferation suggesting that this receptor may play a synergistic role together with the MMP/angiostatin axis by directly regulating endothelial cell proliferation. The role of integrin o_1 and the MMP/angiostatin axis in tumor progression will be explored in the following aims. 1) Analyze in vivo i) the role of the MMP/angiostatin axis in the control of primary vs. metastatic human tumors, ii) whether MMP inhibitors can be successfully used in the prophylaxis of primary vs. metastatic cancers. II) Distinguish between a direct role of integrin c_l in the control of endothelial cell proliferation and the effect of MMPs or angiostatin by crossing the otl-null mice with the plasminogen- or MMP-null mice. III) Analyze in real time the effect of angiostatin and MMP inhibitors on tumor vascularization using the cutaneous window assay. These studies will help us to determine how stinaulation of the MMP/angiostatin axis can be used as a tool to inhibit specifically tumor vaseularization and growth.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Endo180 binds to the C-terminal region of type I collagen.
Endo180 与 I 型胶原蛋白的 C 末端区域结合。
DOI: 10.1074/jbc.m501155200
发表时间: 2005
期刊: The Journal of biological chemistry
影响因子: --
作者: [Thomas,EmilyK, Nakamura,Misa, Wienke,Dirk, Isacke,ClareM, Pozzi,Ambra, Liang,Peng]
通讯作者: Liang,Peng
ASMB 2023: Tissue, Matrix, and Pathobiology
2023 Fibronectin, Integrins and Related Molecules Gordon Research Conference and Gordon Research Seminar
  • 批准号:
    10608783
  • 项目类别:
  • 资助金额:
    $1.5万
  • 财政年份:
    2022
  • 负责人:
    AMBRA POZZI
  • 依托单位:
BLR&D Merit Review Research Career Scientist (RCS) Award (IK6)
  • 批准号:
    10618237
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2020
  • 负责人:
    AMBRA POZZI
  • 依托单位:
BLR&D Merit Review Research Career Scientist (RCS) Award (IK6)
  • 批准号:
    10451496
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2020
  • 负责人:
    AMBRA POZZI
  • 依托单位:
海外基金